Your browser is no longer supported. Please, upgrade your browser.
IMV [NASD]
IMV Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own0.61% Shs Outstand79.18M Perf Week-2.38%
Market Cap125.21M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float75.33M Perf Month-3.91%
Income-40.30M PEG- EPS next Q-0.13 Inst Own21.31% Short Float1.15% Perf Quarter-22.15%
Sales0.30M P/S417.38 EPS this Y-4.90% Inst Trans- Short Ratio2.03 Perf Half Y-12.14%
Book/sh0.52 P/B2.37 EPS next Y- ROA-75.50% Target Price- Perf Year-66.76%
Cash/sh0.45 P/C2.74 EPS next 5Y- ROE-115.50% 52W Range1.19 - 4.60 Perf YTD0.82%
Dividend- P/FCF- EPS past 5Y-13.60% ROI-89.70% 52W High-72.83% Beta1.80
Dividend %- Quick Ratio5.20 Sales past 5Y18.30% Gross Margin- 52W Low5.04% ATR0.09
Employees77 Current Ratio5.20 Sales Q/Q1627.80% Oper. Margin- RSI (14)44.19 Volatility6.91% 7.39%
OptionableYes Debt/Eq0.25 EPS Q/Q-39.10% Profit Margin- Rel Volume0.26 Prev Close1.23
ShortableYes LT Debt/Eq0.24 EarningsNov 11 BMO Payout- Avg Volume427.49K Price1.25
Recom2.20 SMA20-2.15% SMA50-11.49% SMA200-33.10% Volume10,221 Change1.63%
Sep-22-21Initiated Cantor Fitzgerald Overweight $4
Jul-23-21Resumed Wells Fargo Overweight $14
May-18-20Upgrade Wells Fargo Equal Weight → Overweight
Apr-01-20Downgrade B. Riley FBR Buy → Neutral $7 → $3
Feb-25-20Downgrade Wells Fargo Overweight → Equal Weight
Jan-28-20Initiated BTIG Research Buy $8
Jan-21-20Upgrade Wells Fargo Equal Weight → Overweight
Nov-26-19Initiated Oppenheimer Outperform
Oct-28-19Initiated Wells Fargo Market Perform
May-29-19Initiated B. Riley FBR Buy
Mar-25-19Initiated H.C. Wainwright Buy $11.50
Jan-13-22 09:16AM  
Jan-12-22 07:05AM  
Jan-05-22 07:05AM  
Dec-22-21 07:05AM  
Dec-21-21 07:05AM  
Dec-20-21 07:05AM  
Dec-02-21 07:05AM  
Nov-30-21 07:05AM  
Nov-23-21 08:05AM  
Nov-22-21 08:05AM  
Nov-17-21 11:32AM  
Nov-10-21 05:05PM  
Nov-09-21 08:05AM  
Nov-04-21 07:05AM  
Oct-07-21 09:05AM  
Oct-01-21 08:05AM  
Sep-30-21 04:35PM  
Sep-01-21 07:05AM  
Aug-11-21 10:01PM  
07:05AM  
Aug-10-21 07:11AM  
Aug-04-21 08:30AM  
Aug-02-21 07:05AM  
Jul-29-21 07:05AM  
Jul-20-21 10:05AM  
Jul-15-21 09:11AM  
07:05AM  
Jul-14-21 04:05PM  
Jun-18-21 04:05PM  
Jun-12-21 03:42AM  
Jun-09-21 07:05AM  
Jun-08-21 07:05AM  
May-13-21 07:05AM  
May-12-21 07:30PM  
07:05AM  
06:15AM  
May-11-21 07:05AM  
May-10-21 07:05AM  
Apr-29-21 07:05AM  
Apr-13-21 07:05AM  
Apr-09-21 08:30AM  
Apr-08-21 05:30AM  
Apr-07-21 08:54AM  
07:05AM  
Mar-25-21 07:05AM  
Mar-17-21 02:30PM  
07:05AM  
06:15AM  
Mar-10-21 12:30PM  
Mar-08-21 07:05AM  
Mar-01-21 07:05AM  
Jan-04-21 07:05AM  
Dec-28-20 07:38AM  
07:05AM  
Dec-10-20 06:00AM  
Dec-09-20 10:40AM  
Dec-06-20 08:15AM  
Dec-03-20 07:10AM  
Nov-13-20 07:05AM  
Nov-12-20 07:05AM  
06:15AM  
Nov-10-20 07:05AM  
Nov-09-20 05:05PM  
08:00AM  
Nov-04-20 05:05PM  
Oct-29-20 07:05AM  
Oct-16-20 04:48PM  
04:53AM  
Oct-15-20 07:05AM  
Oct-08-20 07:05AM  
Sep-16-20 07:05AM  
Sep-04-20 06:01PM  
Sep-02-20 10:22AM  
Aug-26-20 07:05AM  
Aug-12-20 08:25AM  
07:05AM  
Aug-11-20 09:28AM  
Aug-05-20 12:30PM  
09:00AM  
07:05AM  
Aug-03-20 07:05AM  
Jul-29-20 07:05AM  
Jul-23-20 10:20AM  
Jul-20-20 03:35PM  
07:05AM  
Jul-17-20 08:51AM  
Jul-14-20 11:07AM  
09:01AM  
07:05AM  
Jun-30-20 05:05PM  
Jun-29-20 05:05PM  
Jun-19-20 04:26PM  
Jun-15-20 07:05AM  
Jun-08-20 07:05AM  
May-29-20 08:05AM  
May-21-20 07:05AM  
May-15-20 08:25AM  
07:05AM  
May-07-20 12:30PM  
10:16AM  
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.